Pharvaris (PHVS) Profit After Tax (2020 - 2026)
Pharvaris (PHVS) posted Profit After Tax of -$45.9 million for Q1 2026, up 15.65% on a QoQ basis from -$54.4 million in Q4 2025, and up 5.85% year-over-year from -$43.4 million in Q1 2025.
Pharvaris (PHVS) Profit After Tax (2020 - 2026) Analysis & Trends
Pharvaris' Profit After Tax history runs 7 years deep, the most recent figure standing at -$45.9 million for Q1 2026.
- Quarterly Profit After Tax rose 5.85% year-over-year to -$45.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$195.2 million (down 19.23% YoY) and the FY2025 annual result came in at -$198.5 million, down 36.64% from the prior year.
- Profit After Tax was -$45.9 million for Q1 2026 at Pharvaris, up from -$54.4 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$8.6 million in Q3 2022 and bottomed at -$54.4 million in Q4 2025.
- A 5-year average of -$34.0 million and a median of -$35.2 million in 2023 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax climbed 26.41% — and 2023, when it tumbled 200.18%.
- Pharvaris' Profit After Tax stood at -$40.0 million in 2022, then advanced by 11.89% to -$35.2 million in 2023, then retreated by 5.42% to -$37.1 million in 2024, then sank by 46.47% to -$54.4 million in 2025, then advanced by 15.65% to -$45.9 million in 2026.
- Business Quant data shows PHVS's Profit After Tax at -$45.9 million in Q1 2026, -$54.4 million in Q4 2025, and -$43.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Pharvaris | 2.23 Bn | 1.94 Bn | - | -45.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.89 Mn |
| Dec 31, 2025 | -54.41 Mn |
| Sep 30, 2025 | -43.42 Mn |
| Jun 30, 2025 | -51.48 Mn |
| Mar 31, 2025 | -48.75 Mn |
| Dec 31, 2024 | -37.15 Mn |
| Sep 30, 2024 | -45.81 Mn |
| Jun 30, 2024 | -32.02 Mn |
| Mar 31, 2024 | -30.44 Mn |
| Dec 31, 2023 | -35.23 Mn |
| Sep 30, 2023 | -25.69 Mn |
| Jun 30, 2023 | -23.85 Mn |
| Mar 31, 2023 | -24.29 Mn |
| Dec 31, 2022 | -39.99 Mn |
| Sep 30, 2022 | -8.56 Mn |
| Jun 30, 2022 | -13.47 Mn |
| Mar 31, 2022 | -17.99 Mn |
| Dec 31, 2021 | 34,559.40 Bn |
| Sep 30, 2021 | -10.62 Mn |
| Jun 30, 2021 | -18.30 Mn |